There has been little improvement in the prognosis of glioblastoma multiforme (GBM) despite a number of therapeutic modalities that have been developed. Immunotherapy presents a therapeutic challenge with a different strategy from radiation therapy and chemotherapy. Based on the tumor-specific immune reactions, Ohno's group developed the use of formalin-fixed sections instead of live target tumor cells and formulated an autologous formalin-fixed tumor vaccine (AFTV). This paper reports the results of preliminary clinical trials and prospective clinical trial directed to the evaluation of the therapeutic efficacy of the AFTV concomitant with fractionated radiotherapy (FRT) in cases of initially-diagnosed glioblastoma multiforme (GBM).
|Number of pages||8|
|Publication status||Published - 2010 Nov 1|
- Autologous formalin-fixed tumor vaccine
- Clinical trial
ASJC Scopus subject areas
- Cancer Research